Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous lirentelimab for moderate-to-severe atopic dermatitis inadequately controlled by topical treatments
2022-001625-79Phase 2Terminated
- Sponsor
- Allakos Inc.
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Subcutaneous lirentelimab with Placebo (2 arms). Primary endpoint: EASI-75 response at Week 14. Started Aug 2022; status: terminated.
02
Drugs
lirentelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-001625-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001625-79.